Ginkgo Bioworks Holdings (NYSE:DNA) is preparing to release its quarterly earnings on Thursday, 2026-02-26. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Ginkgo Bioworks Holdings to report an earnings per share (EPS) of $-1.39.
Ginkgo Bioworks Holdings bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Past Earnings Performance</h3>
Last quarter the company missed EPS by $0.21, which was followed by a 20.8% drop in the share price the next day.
Here's a look at Ginkgo Bioworks Holdings's past performance and the resulting price change:
<table>
<thead>
<tr>
<th>Quarter</th>
<th align="right">Q3 2025</th>
<th align="right">Q2 2025</th>
<th align="right">Q1 2025</th>
<th align="right">Q4 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td align="right">-1.24</td>
<td align="right">-1.44</td>
<td align="right">-1.23</td>
<td align="right">-1.30</td>
</tr>
<tr>
<td>EPS Actual</td>
<td align="right">-1.45</td>
<td align="right">-1.10</td>
<td align="right">-1.68</td>
<td align="right">-2.00</td>
</tr>
<tr>
<td>Price Change %</td>
<td align="right">-20.80</td>
<td align="right">-8.69</td>
<td align="right">14.73</td>
<td align="right">-11.47</td>
</tr>
</tbody>
</table>
<img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1772042555_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="eps graph" width="700" height="500" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1772042555_0.png"/>

<h3>Performance of Ginkgo Bioworks Holdings Shares</h3>
Shares of Ginkgo Bioworks Holdings were trading at $8.86 as of February 24. Over the last 52-week period, shares are up 7.99%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>About Ginkgo Bioworks Holdings</h3>
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&amp;D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.
<h3>A Deep Dive into Ginkgo Bioworks Holdings's Financials</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Challenges: Ginkgo Bioworks Holdings's revenue growth over 3 months faced difficulties. As of 30 September, 2025, the company experienced a decline of approximately -56.39%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Ginkgo Bioworks Holdings's net margin is impressive, surpassing industry averages. With a net margin of -207.93%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Ginkgo Bioworks Holdings's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -13.77%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -6.67%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Ginkgo Bioworks Holdings's debt-to-equity ratio is below the industry average at 0.76, reflecting a lower dependency on debt financing and a more conservative financial approach.
To track all earnings releases for Ginkgo Bioworks Holdings visit their earnings calendar on our site.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SBIO

DNABW

IBBQ

Ginkgo Bioworks Holdings (NYSE:DNA) is set to announce its quarterly earnings on February 26, 2026, with analysts predicting an EPS of $-1.39. Investors are keen on positive guidance following a previous EPS miss that led to a 20.8% drop in share price. Currently trading at $8.86, shares have risen 7.99% over the past year. The company faces revenue challenges, with a 56.39% decline in growth, but maintains a strong net margin of -207.93%. Ginkgo operates in cell programming and biosecurity, with a conservative debt-to-equity ratio of 0.76.

Insights into Ginkgo Bioworks Holdings's Upcoming Earnings